Loading live market data…

Apexigen, Inc.

NASDAQ:APGN

$0.3851 USD

$0.03 (8.48%)

Volume
94.43K
Average Volume
52.6K
Market Capitalization
$9.57M
P/E Ratio
-0.24
Dividend Yield
0.00%
Price Target
$
Year High
$8.28
Year Low
$0.33
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.29

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Xiaodong Yang
Industry Biotechnology
Sector Healthcare
Current Symbol APGN
CUSIP None
CIK 0001814140
Web https://www.apexigen.com
Phone 650-931-6236
Currency USD
Employees 11
Country US

Liquidity

Debt-to-Equity Ratio 0.02
Payout Ratio 0.00
Current Ratio 1.29
Quick Ratio 1.29
Cash Ratio 0.90

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow -1.55
Price / Cash Flow -0.31
Price / Book 1.19

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating N/A
Rating Score(0-5) 0
Research Coverage 1 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-1.59
Trailing P/E Ratio -0.24
PEG Ratio 0.00
P/E Growth 0.00
Net Income $-31.45M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity 48.27%
Return on Assets -137.62%

Financials Score

AltmanZ Score -28.91
Piotroski Score 3.00
Working Capital -2.8M
Total Assets 13.08M
Ebit -34.94M
Market Cap 9.57M
Total Liabilities 15.4M

Poll Results

About Apexigen, Inc. (NASDAQ:APGN) Stock

Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, ... through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.

Frequently Asked Questions

What is the current Apexigen, Inc. (APGN) stock price?

Apexigen, Inc.(NASDAQ:APGN) stock price is $0.3851 in the last trading session. During the trading session, APGN stock reached the peak price of $8.28 while $0.331 was the lowest point it dropped to. The percentage change in APGN stock occurred in the recent session was 8.48% while the dollar amount for the price change in APGN stock was $0.03.

APGN's industry and sector of operation?

The NASDAQ listed APGN is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of APGN?

Francis W. Sarena | Pres & Chief Operating Officer
Xiaodong Yang | Chief Executive Officer & Director
|
|
|

How many employees does APGN have?

Number of APGN employees currently stands at 11. APGN operates from 75 Shoreway Road, San Carlos, CA 94070, US.

Link for APGN official website?

Official Website of APGN is: https://www.apexigen.com

How do I contact APGN?

APGN could be contacted at phone #650-931-6236 and can also be accessed through its website. APGN operates from 75 Shoreway Road, San Carlos, CA 94070, US.

How many shares of APGN are traded daily?

The average number of APGN shares traded daily for last 3 months was 52.6K.

What is the market cap of APGN currently?

The market value of APGN currently stands at $9.57M with its latest stock price at $0.3851